Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Young patients with low-risk, relapsed Hodgkin lymphoma may be able to avoid transplant, data from 3 studies suggest.

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC ...

As part of the reshuffle, I-Mab will prioritise the advancement of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, ...

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a paper published in the ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...

Monoclonal Antibodies IndustryThe global monoclonal antibodies (mAbs) industry, valued at USD 186 billion in 2021, is ...